Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Therapeutic Antibody Start-Ups

This article was originally published in Start Up

Executive Summary

After more than a decade of anticipation, pharmas have now clearly recognized the value of antibodies as therapeutics. And biotechs can offer discovery tools and development expertise.

You may also be interested in...

Rinat Neuroscience Corp.

None of the marketed humanized monoclonal antibodies and very few of those in development target nervous system disorders. Rinat Neuroscience Corp. hopes to turn heads by pioneering highly targeted antibody therapies for pain, neuropathy and other neural disorders.

Acceptys Inc.

With an engineered cell line, Acceptys can capture, screen and produce naturally occurring human antibodies ex vivo.

KaloBios Inc.

A handful of companies control the intellectual property for and offer access to human antibody discovery and engineering capabilities. KaloBios thinks it will be one of them, having built a platform of proprietary in vitro technologies for creating and optimizing human antibodies. To fully leverage the value of its technology platform, the start-up is becoming vertically integrated, via a merger with Celscia Therapeutics, which will give it the capability to not only discover and engineer clinically relevant antibodies, but also to develop them and bring them through to the clinic quickly.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts